The in vitro cytotoxic effect of mitoxantrone in combination with fludarabine or pentostatin in B-cell chronic lymphocytic leukemia

Haematologica

Volumn 82, Issue 5, 1997, Pages 560-565

  Morabito, Fortunato ^a   Callea, Ida ^a   Console, Giuseppe ^a   Stelitano, Caterina ^a   Sculli, Giuseppina ^b   Filangeri, Monica ^a   Oliva, Bianca ^a   Musolino, Caterina ^b   Iacopino, Pasquale ^a   Brugiatelli, Maura ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Apoptosis; Chronic lymphocytic leukemia; Fludarabine; Mitoxantrone; MTT assay; Pentostatin

Indexed keywords

FLUDARABINE PHOSPHATE; MITOXANTRONE; PENTOSTATIN;

APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LD 50; LEUKEMIA CELL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; DRUG INTERACTIONS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LEUKEMIA, B-CELL, CHRONIC; MITOXANTRONE; PENTOSTATIN; TUMOR CELLS, CULTURED; VIDARABINE;

EID: 0031465472     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bowden GT, Roberts R, Alberts DS, et al. Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene. Cancer Res 1985; 45:4915-20.
2. Paciucci PA, Davis RB, Holland JF et al. Mitoxantrone and costant infusion etoposide for relapsed and refractory acute myelocytic leukemia. Am J Clin Oncol Cancer 1990; 13:516-9.
3. Bajetta E, Buzzoni R, Valagussa P, et al. Mitoxantrone: an active agent in refractory non-Hodgkins lymphomas. Am J Clin Oncol 1988; 11:100-3.
4. McLaughlin P, Hagemeister FB, Swan F, et al. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 1994; 12:1343-8.
5. Saven A, Lee T, Kosty M, Piro L Cladribine and mitoxantrone dose escalation in indolent non-Hodgkins lymphoma. J Clin Oncol 1996; 14:2139-44.
6. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995; 19:1052-7.
7. Brugiatelli M, Jaksic B, Planinc-Peraica A, et al. Treatment of chronic lymphocytic leukemia in early and stable phase of the disease: long-term results of a randomized trial. Eur J Haematol 1995; 55:158-63.
8. Jaksic B, Brugiatelli M, Krc I, et al. Comparison of high-dose chlorambucil versus Binets modified CHOP regimen in B-cell chronic lymphocytic leukemia in advanced phase: results of an international multicentric randomized trial. Cancer 1997; 79:2107-14.
9. The French Cooperative Group on CLL. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 1996; 347:1432-8.
10. Molica S, De Rossi G, Luciani M, Levato D. Prognostic features and therapeutical approaches in B-cell chronic lymphocyitc leukemia: an update. Haematologica 1995; 80:176-93.
11. Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 73:2013-26.
12. Di Simone D, Testi R, Caracciolo F, et al. Glutathione-S-transferase activity and multidrug resistance phenotype in chronic lymphocytic leukemia: do they have any clinical relevance? Haematologica 1995; 80:103-7.
13. Morabito F, Messina G, Oliva B, et al. In vitro chemosensitivity of chronic lymphocytic leukemia B-cells to multidrug regimen (CEOP) compounds using the MTT colorimetric assay. Haematologica 1993;78:213-8.
14. Silber R, Degar B, Costin D, et al. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood 1994; 84: 3440-6.
15. Morabito F, Callea I, Rodin A, et al. Modulation of purine analogs-and chlorambucil-induced cytotoxicity by alpha-interferon and interleukin-2 in chronic lymphocytic leukemia. Leukemia 1995; 9:1425-33.
16. Morabito F, Stelitano C, Callea I, et al. In vitro chemosensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2′-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features. Haematologica 1996; 81:224-31.
17. Morabito F, Callea I, Irrera G, et al. In vitro improvement of chlorambucil-induced cytotoxicity by deflazacort and 6-methylprednisolone in B-cell chronic lymphocytic leukemia. Eur J Haematol 1997; (in press).
18. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87:4990-7.
19. Valeriote F, Lin HS. Synergistic interaction of anticancer agents: a cellular prospective. Cancer Chemother Rep 1975; 59: 895-9.
20. Sondak OK, Korn EL, Kern DH. In vitro testing of chemotherapeutic combinations in a rapid thymidine incorporation assay. Int J Cell Cloning 1988; 6:378-81.
21. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139:271-9.
22. Gruber A, Liliemark J, Tidefelt U et al. Pharmacokinetics of mitoxantrone in plasma and leukemic cells during treatment of patients with acute non-lymphocytic leukemia. Leuk Lymphoma 1992; 6: 493-6.
23. Smyth JF, Paine RM, Jackman AL, et al. The clinical pharmacology of the adenosine deaminase inhibitor 2-deoxycoformycin. Cancer Chemother Pharmacol 1980; 5:93-101.
24. Danhauser L, Plunkett W, Keating M, Cabanillas F. 9-beta-D- arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells with relapsed leukemia and lymphoma. Cancer Chemother Pharmacol 1986; 18:142-5.
25. Rai KR, Peterson B, Elias L, et al. A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG, CTG/NCI-C and ECOG inter-group study. Blood 1996; 88(suppl 1):141a.
26. Jaksic B, Delmer A, Brugiatelli M, et al. Interim analysis of a randomised EORTC study comparing high dose chlorambucil (HD-CLB) vs fludarabine (FAMP) in untreated B-cell chronic lymphocytic leukaemia (CLL) [abstract]. VII International Workshop on CLL 1997;064a.
27. Tallman MS, Hakimian D. Purine nucleoside analogs: emerging roles in indolente lymphoproliferative disorders. Blood 1995; 86: 2463-74.
28. O'Brien S, Kantarjian H, Ellis A, Zwelling L, Estey E, Keating M. Topotecan in chronic lymphocytic leukemia. Cancer 1995; 75: 1104-8.
29. Johnston JB, Verburg L, Shore T, Williams M, Israels LG, Begleiter A. Combination therapy with nucleoside analogs and alkylating. Leukemia 1994; 8(suppl 1):140-3.
30. Frankfurt OS, Byrnes JJ, Seckinger D, Sugarbaker EV. Apoptosis (programmed cell death) and the evaluation of chemosensitivity in chronic lymphocytic leukemia and lymphoma. Oncol Res 1993; 5: 37-42.
31. Ments F, Mossalayi D, Quaaz F, et al. Theophydine synergizes with chlorambucil in inducing apoptosis of B-chronic lymphocytic leukemia cells. Blood 1996; 88:2172-82.
32. Callea V, Morabito F, Luise F, et al. Clinical significance of slL2R, sCD23, slCAM-1, IL6 and sCD14 serum levels in B-cell chronic lymphocytic leukemia. Haematologica 1996; 81:310-5.